Search Results - "Ngo, Leock Y."

Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal‐onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open‐label Study 342 (FREEDOM) by Husni, Ryan Edbert, Ngo, Leock Y., Senokuchi, Hirofumi, Patten, Anna, Hiramatsu, Hidetaka, Watanabe, Kazuaki, Yamamoto, Takamichi

“…Objective This post hoc analysis evaluated whether continued treatment with perampanel monotherapy beyond initial titration may be appropriate for patients…”
Get full text

A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy by Hahn, Angelika F., Beydoun, Said R., Lawson, Victoria, Oh, MyungShin, Empson, Victoria G., Leibl, Heinz, Ngo, Leock Y., Gelmont, David, Koski, Carol L.

“…Intravenous immunoglobulin (IVIG) has become the standard treatment for multifocal motor neuropathy (MMN) based on limited data. To critically assess the…”
Get full text

Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy by Hanaya, Ryosuke, Kubota, Yuichi, Mizobuchi, Masahiro, Iida, Koji, Ono, Tomonori, Motooka, Hiromichi, Nakano, Naoki, Fujimoto, Ayataka, Iwasaki, Masaki, Fukuda, Masafumi, Kondo, Akihiko, Uruno, Katsuhisa, Yamamuro, Shintaro, Yamaguchi, Kohei, Onishi, Kisaki, Ngo, Leock Y, Inoue, Yushi

“…Perampanel is an oral anti-seizure medication, which is approved in Japan for focal-onset seizures, with/without focal to bilateral tonic-clonic seizures, as…”
Get full text

Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures by Fogarasi, Andras, Flamini, Robert, Milh, Mathieu, Phillips, Steven, Yoshitomi, Shinsaku, Patten, Anna, Takase, Takao, Laurenza, Antonio, Ngo, Leock Y.

“…Objective Study 311 (NCT02849626) was a global, multicenter, open‐label, single‐arm study that assessed safety, tolerability, pharmacokinetics, and…”
Get full text

Perampanel as monotherapy or first adjunctive therapy in pediatric and adult patients with epilepsy: the first United States-based phase IV open-label ELEVATE study by Punia, Vineet, Klein, Pavel, Mihaylova, Temenuzhka, Biton, Victor, Samad, Omar, Ngo, Leock Y., Kumar, Dinesh, Malhotra, Manoj

“…ELEVATE (Study 410; NCT03288129) is the first prospective, multicenter, open-label, Phase IV study of perampanel as monotherapy or first adjunctive therapy in…”
Get full text

Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332 by Resnick, Trevor, Patten, Anna, Ngo, Leock Y., Malhotra, Manoj

“…[Display omitted] •Long-term seizure freedom with perampanel for FBTCS and GTCS was assessed.•Post hoc analyses were based on data from core studies and…”
Get full text

Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis by Omatsu, Hirowo, Watanabe, Toshihide, Kira, Ryutaro, Ishiba, Kaeko, Patten, Anna, Takase, Takao, Ngo, Leock Y

“…•We assessed perampanel outcomes for pediatric Japanese patients from study 311.•Adjunctive perampanel for FOS was generally safe and well…”
Get full text

A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy by Maguire, Melissa, Ben-Menachem, Elinor, Patten, Anna, Malhotra, Manoj, Ngo, Leock Y.

“…•Observational study of perampanel (mean dose: 4.6 mg/day) in 493 patients with epilepsy.•Treatment-emergent adverse events (TEAEs) were consistent with the…”
Get full text

Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of primary generalized tonic–clonic seizures by Kerr, Wesley T., Ngo, Leock Y., Zhu, Liang, Patten, Anna, Cheng, Jocelyn Y., Reddy, Advith S., French, Jacqueline A.

“…Objective Static assignment of participants in randomized clinical trials to placebo or ineffective treatment confers risk from continued seizures. An…”
Get full text

Time to exceed pre‐randomization monthly seizure count for perampanel in participants with primary generalized tonic–clonic seizures: A potential clinical end point by Kerr, Wesley T., Brandt, Christian, Ngo, Leock Y., Patten, Anna, Cheng, Jocelyn Y., Kramer, Lynn, French, Jacqueline A.

“…Objective To evaluate the exploratory time to exceed pre‐randomization seizure count (T‐PSC) in the determination of efficacy of adjunctive perampanel in…”
Get full text

Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy by Brandt, Christian, Wechsler, Robert T., O’Brien, Terence J., Patten, Anna, Malhotra, Manoj, Ngo, Leock Y., Steinhoff, Bernhard J.

“…•We assessed myoclonic and absence seizure outcomes with perampanel from Study 332.•Add-on perampanel and placebo reduced myoclonic and absence seizure…”
Get full text

Health-related quality of life in pediatric patients with partial onset seizures or primary generalized tonic-clonic seizures receiving adjunctive perampanel by Trigg, Andrew, Brohan, Elaine, Cocks, Kim, Jones, Amy, Tahami Monfared, Amir A., Chabot, Isabelle, Meier, Genevieve, Campbell, Renee, Li, Huimin, Ngo, Leock Y.

“…•Perampanel use in children with partial onset/primary generalized tonic-clonic seizures.•Quality of life was stable over time from Baseline following 23 and…”
Get full text

Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study by Hussein, Ziad, Majid, Oneeb, Boyd, Peter, Aluri, Jagadeesh, Ngo, Leock Y, Reyderman, Larisa

“…Intravenous (IV) drug administration enables treatment of epilepsy when oral administration is temporarily not feasible. Perampanel is a once‐daily antiseizure…”
Get full text

Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter by PATIL, S. D, NGO, L. Y, GLUE, P, UNADKAT, J. D

Get full text

An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal by Altorjay, Áron, Szabó, Éva, Boda, Zoltán, Kramer, Ludwig, Ngo, Leock Y, Engl, Werner, Firth, Clair L, Ahlstrom, Erik R, Gelmont, David M, Pabinger, Ingrid

“…Abstract Introduction Prothrombin complex concentrates (PCCs) are a common treatment option for the reversal of oral anticoagulation with vitamin K antagonists…”
Get full text

The Gammaglobulin Alzheimer Partnership Study (GAP): Design, screening, enrollment and futility analysis results by Relkin, Norman, Gessert, Devon, Stokes, Karen, Adamiak, Basia, Ngo, Leock Y, Thomas, Ronald, Gelmont, David, Aisen, Paul

Get full text

Structure-inhibitory profiles of nucleosides for the human intestinal N1 and N2 Na+-nucleoside transporters by PATIL, Shivakumar D, NGO, Leock Y, UNADKAT, Jashvant D

“…To determine the structure-inhibitory profiles of nucleosides for the N1 and N2 Na+-nucleoside transporters of the human intestine. The uptake of 3H-labeled…”
Get full text

Pharmacokinetics of Azithromycin Administered Alone and with Atovaquone in Human Immunodeficiency Virus-Infected Children by NGO, L. Y, YOGEV, R, DANKNER, W. M, HUGHES, W. T, BURCHETT, S, JING XU, SADLER, B, UNADKAT, J. D

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Safety and tolerability of an intravenously administered alpha1-proteinase inhibitor at an increased infusion rate: a novel, randomized, placebo-masked, infusion rate-controlled, crossover study in healthy adults by Dyck-Jones, Jacqueline, Ngo, Leock Y., Haeberle, Adam, Gelmont, David, Yel, Leman

“…Purpose: Alpha1-proteinase inhibitor (A1PI) is indicated for chronic augmentation therapy in adults with emphysema due to congenital deficiency of A1PI. An…”
Get full text

Long-term Safety and Efficacy of Adjunctive Perampanel in Pediatric Patients (Aged 4 to <12 years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) in Study 311 (413) by Flamini, Robert, Patten, Anna, Ngo, Leock Y.

“…Abstract only…”
Get full text